JP7483699B2 - 腫瘍の進行を制御するためまたは抗腫瘍免疫を回復するための、マクロファージと、照射された白血球との共培養物から得られる上清 - Google Patents
腫瘍の進行を制御するためまたは抗腫瘍免疫を回復するための、マクロファージと、照射された白血球との共培養物から得られる上清 Download PDFInfo
- Publication number
- JP7483699B2 JP7483699B2 JP2021520460A JP2021520460A JP7483699B2 JP 7483699 B2 JP7483699 B2 JP 7483699B2 JP 2021520460 A JP2021520460 A JP 2021520460A JP 2021520460 A JP2021520460 A JP 2021520460A JP 7483699 B2 JP7483699 B2 JP 7483699B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- leukocytes
- macrophages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006228 supernatant Substances 0.000 title claims description 26
- 210000000265 leukocyte Anatomy 0.000 title claims description 13
- 238000003501 co-culture Methods 0.000 title claims description 9
- 230000005809 anti-tumor immunity Effects 0.000 title claims description 7
- 210000002540 macrophage Anatomy 0.000 title claims description 7
- 206010061309 Neoplasm progression Diseases 0.000 title claims description 4
- 230000005751 tumor progression Effects 0.000 title claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 230000035899 viability Effects 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 238000011394 anticancer treatment Methods 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 230000001143 conditioned effect Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 description 22
- 230000004054 inflammatory process Effects 0.000 description 22
- 230000004614 tumor growth Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 230000028709 inflammatory response Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000006020 chronic inflammation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims (11)
- 腫瘍の進行を制御するため、または抗腫瘍免疫を回復するために使用される医薬製剤であって、マクロファージと照射された白血球との間の共培養液の上清を含み、
ここで、前記マクロファージは、M-CSF(マクロファージコロニー刺激因子)の存在下で培養された白血球から由来する、医薬製剤。 - 前記マクロファージは、白血球であることを特徴とする、請求項1に記載の医薬製剤。
- 前記白血球は、全血から得られるバフィーコートから単離されることを特徴とする、請求項1および2に記載の医薬製剤。
- 前記白血球の一部は、洗浄され、所定の培地に再懸濁され、次いで、分化因子を受け取る第1のポケット内に配置され、細胞の生存能力を維持する条件下で数日間、好ましくは3日間保存され、次いで、新鮮な所定の培地を再び受け取り、次いで、数日間、好ましくは4日間そのまま放置されてマクロファージが生成されることを特徴とする、請求項3に記載の医薬製剤。
- 前記白血球の別の部分は、+10℃未満の温度で保存される第2のポケット内に配置されることを特徴とする、請求項4に記載の医薬製剤。
- 前記第2のポケットは、照射された培地から解放された後に、その培地から解放され、次いで、細胞の生存能力を維持する条件下で、前記第2のポケットおよびその内容物を分泌培地内に配置されることを特徴とする、請求項5に記載の医薬製剤。
- 前記第2のポケットの内容物を、事前にその培地から解放された前記第1のポケットに移され、2つの前記ポケットのセットは、調整された上清が生成されるまでの期間、細胞の生存能力を維持する条件下で保存されて、白血球間の共培養物が生成されることを特徴とする、請求項6に記載の医薬製剤。
- 前記共培養物から得られた上清は、新しいポケットに集められ、濾過され、-80℃を超えない低温で保存されることを特徴とする、請求項7に記載の医薬製剤。
- 単独でまたは他の抗癌治療と共に、癌の治療に使用されることを特徴とする、請求項1~8のいずれか1項に記載の医薬製剤。
- 前記癌は、特にリンパ腫、白血病、肉腫および癌腫、より正確にはT細胞リンパ腫、B細胞リンパ腫、メラノーマおよび結腸癌の一種であることを特徴とする、請求項9に記載の医薬製剤。
- 請求項9または10の記載において使用される医薬製剤であって、請求項1~8のいずれか1項に従って複数の白血球源から得られた上清の混合物を含むことを特徴とする、医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1800636A FR3082730B1 (fr) | 2018-06-21 | 2018-06-21 | Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique |
FR1800636 | 2018-06-21 | ||
PCT/EP2019/066406 WO2019243544A1 (fr) | 2018-06-21 | 2019-06-20 | Surnageant de coculture entre macrophages et leucocytes irradiés utilisé pour controler une progression tumorale ou pour restaurer une immunite anti-tumorale |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021528494A JP2021528494A (ja) | 2021-10-21 |
JP7483699B2 true JP7483699B2 (ja) | 2024-05-15 |
Family
ID=63896221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021520460A Active JP7483699B2 (ja) | 2018-06-21 | 2019-06-20 | 腫瘍の進行を制御するためまたは抗腫瘍免疫を回復するための、マクロファージと、照射された白血球との共培養物から得られる上清 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210145874A1 (ja) |
EP (1) | EP3810157B1 (ja) |
JP (1) | JP7483699B2 (ja) |
KR (1) | KR20210022577A (ja) |
CN (1) | CN112334143A (ja) |
CA (1) | CA3101508A1 (ja) |
DK (1) | DK3810157T3 (ja) |
ES (1) | ES2935969T3 (ja) |
FI (1) | FI3810157T3 (ja) |
FR (1) | FR3082730B1 (ja) |
PL (1) | PL3810157T3 (ja) |
WO (1) | WO2019243544A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028573A2 (en) | 1999-10-21 | 2001-04-26 | The Center For The Improvement Of Human Functioning, International, Inc. | Monocyte conditioned medium for cancer treatment |
WO2014106666A1 (en) | 2013-01-07 | 2014-07-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Disease therapy using a tolerogenic pharmaceutical preparation |
JP2018507208A (ja) | 2015-02-18 | 2018-03-15 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000049096A (ko) * | 1996-10-11 | 2000-07-25 | 린다 에스. 스티븐슨 | 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법 |
EP1005531A2 (en) * | 1997-07-21 | 2000-06-07 | Cerus Corporation | Method of treating leukocytes, leukocyte compositions and methods of use thereof |
US20080089875A1 (en) * | 2006-10-13 | 2008-04-17 | Zheng Cui | Methods and compositions for the treatment of cancer |
EP2723381A4 (en) * | 2011-06-21 | 2015-03-18 | Univ Johns Hopkins | FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS |
-
2018
- 2018-06-21 FR FR1800636A patent/FR3082730B1/fr active Active
-
2019
- 2019-06-20 DK DK19734724.8T patent/DK3810157T3/da active
- 2019-06-20 EP EP19734724.8A patent/EP3810157B1/fr active Active
- 2019-06-20 WO PCT/EP2019/066406 patent/WO2019243544A1/fr active Application Filing
- 2019-06-20 KR KR1020207036661A patent/KR20210022577A/ko not_active Application Discontinuation
- 2019-06-20 CN CN201980041571.0A patent/CN112334143A/zh active Pending
- 2019-06-20 FI FIEP19734724.8T patent/FI3810157T3/fi active
- 2019-06-20 JP JP2021520460A patent/JP7483699B2/ja active Active
- 2019-06-20 US US17/252,818 patent/US20210145874A1/en active Pending
- 2019-06-20 ES ES19734724T patent/ES2935969T3/es active Active
- 2019-06-20 CA CA3101508A patent/CA3101508A1/fr active Pending
- 2019-06-20 PL PL19734724.8T patent/PL3810157T3/pl unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028573A2 (en) | 1999-10-21 | 2001-04-26 | The Center For The Improvement Of Human Functioning, International, Inc. | Monocyte conditioned medium for cancer treatment |
WO2014106666A1 (en) | 2013-01-07 | 2014-07-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Disease therapy using a tolerogenic pharmaceutical preparation |
JP2018507208A (ja) | 2015-02-18 | 2018-03-15 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ |
Non-Patent Citations (3)
Title |
---|
Front Immunol,2017年,Vol. 8, Article 71,11 pages |
J Clin Invest,1998年,Vol. 101, No. 4,pp. 890-898 |
Jpn. J. Med. Mycol.,1997年,Vol. 38,pp. 209-214 |
Also Published As
Publication number | Publication date |
---|---|
FR3082730B1 (fr) | 2022-04-22 |
JP2021528494A (ja) | 2021-10-21 |
US20210145874A1 (en) | 2021-05-20 |
DK3810157T3 (da) | 2023-02-06 |
EP3810157A1 (fr) | 2021-04-28 |
CA3101508A1 (fr) | 2019-12-26 |
FI3810157T3 (fi) | 2023-02-28 |
CN112334143A (zh) | 2021-02-05 |
PL3810157T3 (pl) | 2023-03-13 |
WO2019243544A1 (fr) | 2019-12-26 |
FR3082730A1 (fr) | 2019-12-27 |
KR20210022577A (ko) | 2021-03-03 |
ES2935969T3 (es) | 2023-03-13 |
EP3810157B1 (fr) | 2022-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abbas et al. | An overview of cancer treatment modalities | |
Hou et al. | Intestinal stem cells and immune cell relationships: potential therapeutic targets for inflammatory bowel diseases | |
Goldszmid et al. | Host immune response to infection and cancer: unexpected commonalities | |
WO2019056404A1 (zh) | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 | |
Das et al. | Electrical stimulation for immune modulation in cancer treatments | |
JP2019512495A5 (ja) | ||
Wang et al. | The pros and cons of dying tumour cells in adaptive immune responses | |
JP7483699B2 (ja) | 腫瘍の進行を制御するためまたは抗腫瘍免疫を回復するための、マクロファージと、照射された白血球との共培養物から得られる上清 | |
CN111346092A (zh) | 安罗替尼在制备治疗急性髓系白血病药物的新用途 | |
Kuang et al. | Mechanism of exosomes in the tumor microenvironment in the abscopal effect | |
Ajeawung et al. | Progress from clinical trials and emerging non-conventional therapies for the treatment of Medulloblastomas | |
Klotskova et al. | The role of interleukin‐22 in mammalian intestinal homeostasis: Friend and foe | |
CN107536845B (zh) | 一种防治肿瘤的药物及其用途 | |
Mattot et al. | Combined C02-Laser and Alfa Recombinant Interferon Treatment in Five Children with Juvenile Laryngeal Papillomatosis | |
CN111195250A (zh) | 西达本胺联合dice的应用及联合药物 | |
Yu et al. | Killing two birds with one stone: Abscopal Effect Mechanism and its application prospect in radiotherapy | |
WO2017114215A1 (zh) | 重组人钙调磷酸酶b亚基的应用 | |
Molina et al. | A review of IMMUNEPOTENT CRP, a modifier of biological response: efficacy and current practice | |
Nguyen et al. | Neuroblastoma: Molecular Mechanisms and Therapeutic Interventions | |
RU2487727C1 (ru) | Способ лечения больных с рефрактерным и рецидивным течением лимфомы ходжкина | |
KR100522526B1 (ko) | 면역 치료용 수지상 세포의 제조방법 | |
Oth | PAMPering immune responses: spotlight on helper cells for dendritic cell vaccination | |
Razzaq et al. | Cancer: From Theory to Practice–Ideology of Etiology and Treatment | |
Sobti et al. | Advanced Therapeutic Approaches in Cancer Therapy | |
Mollick | Retinal Tumorigenesis and Neurodegeneration: Strategies to Promote Tumor Cell Death and Support Retinal Cell Survival to Preserve Vision |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220525 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240501 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7483699 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |